Full Press Release Details
Altimmune Announces First Quarter 2022 Financial Results and Provides a Corporate Update
Multiple clinical trial data readouts expected in Q3 and Q4 2022
GAITHERSBURG, MD, -- May 12, 2022 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended March 31, 2022 and provided a corporate update.
"We continue to advance the development of pemvidutide, our GLP-1/Glucagon dual receptor agonist and look forward to reporting both weight loss and liver fat reduction data from multiple ongoing clinical trials later this year," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "Based on a greater than 10% weight loss after only 12 weeks of treatment, we believe that pemvidutide has the potential to deliver weight loss comparable to the results of bariatric surgery in people with obesity. In addition, we believe that pemvidutide will have a highly differentiated product profile compared to other products in development-no dose titration, faster weight loss, and robust reductions in lipids. If achieved, we believe these features would translate into greater ease of administration, improved adherence to therapy, and greater potential for cardiovascular benefit."
Recent Highlights and Anticipated Milestones:
Pemvidutide1 (ALT-801)
Upcoming presentations summarizing data from the Phase 1 trial of pemvidutide at international Scientific Meetings
Financial Results for the Three Months Ended March 31, 2022
Conference Call Information
| Date: | Thursday, May 12 |
| Time: | 8:30 am Eastern Time |
| Domestic Dial-in: | (800) 225-9448 |
| International Dial-in: | (203) 518-9708 |
| Conference ID: | ALTQ122 |
| Webcast: | https://edge.media-server.com/mmc/p/j5i9f735 |
Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company's website at www.altimmune.com. The Company has used, and intends to continue to use, the IR portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. By combining GLP-1 and glucagon activity in a single peptide, pemvidutide has the potential to achieve weight loss comparable to the results of bariatric surgery. Pemvidutide incorporates the EuPortTM domain, a proprietary technology that increases its serum half-life for weekly dosing while slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability. In a 12-week Phase 1 clinical trial, pemvidutide-treated subjects demonstrated striking reductions in body weight, liver fat and serum lipids commonly associated with cardiovascular disease.
HepTcell is a novel, investigational, immunotherapeutic comprised of nine synthetic peptides representing conserved hepatitis B (HBV) sequences formulated with IC31 , a TLR9-based adjuvant from Valneva SE. The HBV-directed peptides are designed to drive T cell responses against all HBV genotypes towards a functional cure for chronic HBV in patients of diverse genetic backgrounds.
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell , an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Forward-Looking Statement
Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the timing of the data readouts of the NAFLD trials, drug-drug interaction trial, and the Phase 2 obesity clinical trial of pemvidutide, the timing of the data readouts for the Phase 2 clinical trial of HepTcell, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Altimmune, Inc. (the "Company") may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts from the ongoing conflict in Ukraine and the COVID-19 pandemic, such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates; the Company's ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2021 and our other filings with the SEC, which are available at www.sec.gov.
Investor & Media Contacts:
| Rich Eisenstadt |
| Chief Financial Officer |
| Phone: 240-654-1450 |
| reisenstadt@altimmune.com |
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| March 31, | December 31, | |||||
| 2022 | 2021 | |||||
| (unaudited) | ||||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 179,947 | $ | 190,301 | ||
| Restricted cash | 34 | 34 | ||||
| Total cash, cash equivalents and restricted cash | 179,981 | 190,335 | ||||
| Accounts receivable | 193 | 429 | ||||
| Income tax and R&D incentive receivables | 5,880 | 5,410 | ||||
| Prepaid expenses and other current assets | 5,039 | 7,952 | ||||
| Total current assets | 191,093 | 204,126 | ||||
| Property and equipment, net | 1,337 | 1,448 | ||||
| Intangible assets, net | 12,419 | 12,419 | ||||
| Other assets | 811 | 872 | ||||
| Total assets | $ | 205,660 | $ | 218,865 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 2,205 | $ | 2,034 | ||
| Contingent consideration | 4,310 | 6,090 | ||||
| Accrued expenses and other current liabilities | 12,609 | 10,152 | ||||
| Total current liabilities | 19,124 | 18,276 | ||||
| Other long-term liabilities | 1,668 | 1,454 | ||||
| Total liabilities | 20,792 | 19,730 | ||||
| Commitments and contingencies (Note 16) | ||||||
| Stockholders' equity: | ||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 43,219,896 and 40,993,768 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 4 | 4 | ||||
| Additional paid-in capital | 502,505 | 497,342 | ||||
| Accumulated deficit | (312,601) | (293,171) | ||||
| Accumulated other comprehensive loss, net | (5,040) | (5,040) | ||||
| Total stockholders' equity | 184,868 | 199,135 | ||||
| Total liabilities and stockholders' equity | $ | 205,660 | $ | 218,865 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
| For the Three Months Ended | ||||||
| March 31, | ||||||
| 2022 | 2021 | |||||
| Revenues | $ | 32 | $ | 838 | ||
| Operating expenses: | ||||||
| Research and development | 15,104 | 11,878 | ||||
| General and administrative | 4,427 | 3,821 | ||||
| Total operating expenses | 19,531 | 15,699 | ||||
| Loss from operations | (19,499) | (14,861) | ||||
| Other income (expense): | ||||||
| Interest expense | (62) | (12) | ||||
| Interest income | 21 | 42 | ||||
| Other income (expense), net | 110 | (33) | ||||
| Total other income (expense), net | 69 | (3) | ||||
| Net loss | (19,430) | (14,864) | ||||
| Other comprehensive income - unrealized gain on short-term investments | - | 5 | ||||
| Comprehensive loss | $ | (19,430) | $ | (14,859) | ||
| Net loss per share, basic and diluted | $ | (0.44) | $ | (0.38) | ||
| Weighted-average common shares outstanding, basic and diluted | 43,969,481 | 38,914,990 |